At ASCO, drugmakers to offer options after Keytruda in head and neck cancer

Drugmakers are exploring a variety of approaches to treat head and neck cancers, from bispecific antibodies that target both PD-1 and VEGF to antibody-drug conjugates that deliver more targeted attacks.

Raccontata daendpoints.news